Pulmatrix and Eos SENOLYTIX Announce Merger Agreement to Advance Novel Mitochondrial Therapies to Improve Healthspan Accessibility StatementSkip Navigation Eos SENOLYTIX Logo (PRNewsfoto/Pulmatrix, Inc.) FRAMINGHAM, Mass. and HOUSTON, March 26, 2026 /PRNewswire/ -- Pulmatrix, Inc.(Nasdaq: PULM) ("Pulmatrix") and Eos SENOLYTIX, Inc.("Eos"), a biotechnology company developing novel gerotherapeutic peptides targeting mitochondrial dysfunction in aging-related diseases, today jointly announced a definiti ...